PCM
ARTL icon

Penserra Capital Management’s Artelo Biosciences ARTL Stock Holding History

Penserra Capital Management’s Portfolio ARTL Stock Details ARTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-105
Closed -$27K – 1453
2021
Q2 		$27K Buy
+105
New +$35.9K ﹤0.01% 1104

Other funds holding ARTL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Penserra Capital Management's ARTL Position: Q3 2021 in Review

Penserra Capital Management sold out of Artelo Biosciences (ARTL) in Q3 2021, closing a stake of 105 shares — an estimated $27K sold.

Penserra Capital Management first reported a position in ARTL in Q2 2021 and held it in 1 quarter. The position peaked at $27K in Q2 2021. 15 funds tracked by Wall St. Rank hold ARTL as of Q3 2021.

  • Penserra Capital Management reported no remaining Artelo Biosciences position as of Q3 2021 after selling out during the quarter.
  • Penserra Capital Management sold 105 Artelo Biosciences shares in Q3 2021, an estimated $27K.
  • Penserra Capital Management first reported a position in Artelo Biosciences in Q2 2021 and held it in 1 quarter.
  • Penserra Capital Management's Artelo Biosciences position peaked at $27K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Artelo Biosciences as of Q3 2021.

Based on Penserra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.